Title :

Management of bone fragility in patients with rheumatoid arthritis in France: An analysis of a national health insurance claims database

Author(s) :

Roux, Christian [Auteur]
Hôpital Cochin [AP-HP]
Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques [CRESS (U1153 / UMR_A 1125)]
Cortet, Bernard [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Chapurlat, Roland [Auteur]
Hôpital Edouard Herriot [CHU - HCL]
Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases [LYOS]
Lévy-Weil, Florence [Auteur]
Sanofi Gentilly [Sanofi Gentilly]
Marcadé-Fulcrand, Véronique [Auteur]
Sanofi Gentilly [Sanofi Gentilly]
Desjeux, Guillaume [Auteur]
Sanoïa [Gémenos]
Thomas, Thierry [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Santé Ingénierie Biologie Saint-Etienne [SAINBIOSE]

Journal title :

Joint Bone Spine

Pages :

105340

Publisher :

Elsevier Masson

Publication date :

2022-07

ISSN :

1297-319X

English keyword(s) :

Bone fragility
Case-control study
Fractures
French claims data (EGB)
Rheumatoid arthritis

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Objectives: Rheumatoid arthritis (RA) is considered a major risk factor for fragility fractures. We examined the quality of management of bone fragility in RA patients in a real-life setting.Methods: We performed a ...
Show more >Objectives: Rheumatoid arthritis (RA) is considered a major risk factor for fragility fractures. We examined the quality of management of bone fragility in RA patients in a real-life setting.Methods: We performed a longitudinal case-control retrospective study in a 1/97th random sample of French health care claims database from 2014 to 2016 to determine the extent of bone fragility management in patients with RA compared with non-RA matched controls.Results: Compared to their non-RA controls (n=4652), RA patients (n=1008; mean age: 61.1years; methotrexate: 69.7%; other conventional disease-modifying antirheumatic drugs (cDMARDs): 26.8%; biologic: 26.0%; corticosteroids: 36.9%) had more reimbursements for bone mineral density (BMD) measurements (21.6 vs. 9.2%; OR=2.7 [2.3; 3.3]; P<0.01) and for bisphosphonates (7.1 vs. 3.6%, OR=2.0 [1.5; 2.7]; P<0.05). In patients exposed to corticosteroids, RA patients underwent more BMD assessments than non-RA controls (28.0 vs. 18.8%; OR=1.7 [1.3; 2.2]; P<0.05). RA patients exposed to corticosteroids were more likely to sustain fracture than non-exposed RA patients (5.7 vs. 2.4%, P<0.01). In addition, only when comparing patients exposed to corticosteroids, was there statistical evidence of an association between RA and an increased fracture rate (6.2 vs. 3.5%, P<0.05).Conclusion: Patients with RA exposed to corticosteroids are at high risk of fracture. Patients with RA had more bone fragility management than controls.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Marrow Adiposity & Bone Lab (MABLab) - ULR 4490

Source :

Harvested from HAL